FACT-CHECKED AGAINST PEER-REVIEWED LITERATURE | Sources include PubMed/NCBI, eLife, Nature Communications, Neuropsychopharmacology, and Science. Full citations in the References section.
Table of contents
- LSD Effects & How It Works: What the Science Actually Shows
LSD Effects & How It Works: What the Science Actually Shows
Few substances in modern pharmacology generate more curiosity — and more confusion — than LSD. People want to know what an LSD trip actually feels like, what LSD does to the brain at a neurological level, whether LSD hallucinations are dangerous, and what the real side effects are versus the myths. This article answers each of those questions directly, grounded in the peer-reviewed literature rather than anecdote or cultural mythology.
Understanding LSD effects matters — not just for people who are curious about psychedelics, but for clinicians, researchers, harm reduction practitioners, and anyone navigating conversations about mental health and psychedelic-assisted therapy. The science here is genuinely interesting, and it deserves accurate representation.
General LSD Effects: What Does LSD Do?
What does LSD do at a general level? The effects of LSD are broad, dose-dependent, and profoundly shaped by context. At a standard recreational dose of 75–150 micrograms, LSD produces a cluster of effects that touch virtually every domain of conscious experience — perception, emotion, cognition, sense of self, and the experience of time. This is why a single LSD trip is difficult to summarize concisely: it is not one effect but dozens occurring simultaneously.
A landmark review by Liechti (2017), published in Neuropsychopharmacology, examined all modern clinical LSD studies in healthy subjects and documented the following primary subjective effects using validated psychometric scales:
- Blissful state and euphoria — among the most consistently reported effects at doses of 100 µg and above
- Audiovisual synesthesia — the perceptual blending of senses, where sounds appear as colors or music produces tactile sensations
- Altered meaning of perceptions — ordinary objects or experiences taking on heightened significance or emotional weight
- Derealization — the surrounding environment feeling unreal, dreamlike, or unfamiliar
- Depersonalization — a sense of detachment from one’s body or sense of self
- Mystical or transcendent experiences — feelings of unity, interconnectedness, or awe
- Increased openness and suggestibility
- Enhanced emotional empathy and feelings of closeness to others
Duration follows a predictable pharmacokinetic curve. Onset occurs within 20–60 minutes of oral ingestion. Peak effects arrive between 2 and 5 hours. The total duration of a standard LSD trip is 8 to 12 hours, with residual effects and difficulty sleeping sometimes extending that window. This distinguishes LSD sharply from psilocybin (4–6 hours) and places it among the longest-lasting classic psychedelics.
Key Clinical Finding: A 200 µg oral dose of LSD produced significantly greater bliss, changes in the meaning of perceptions, and insightfulness than a 100 µg dose — confirming clear dose-response effects across subjective dimensions. (Liechti et al., 2017, Neuropsychopharmacology)
What Does LSD Do to the Brain? The Neuroscience
What does LSD do to the brain at a mechanistic level is one of the most intensively studied questions in modern neuropharmacology. The answer centers on one receptor: the serotonin 5-HT2A receptor. LSD is a partial agonist at this receptor — meaning it activates it, but not to the same maximum degree as the endogenous neurotransmitter serotonin. It is the stimulation of 5-HT2A receptors, distributed primarily across the cerebral cortex, that drives the characteristic psychedelic effects.
The critical evidence for this comes from a series of controlled studies in human participants. In a double-blind randomized trial conducted by Preller and colleagues at the University of Zurich, published in eLife (2018), 24 healthy volunteers received LSD (100 µg) with and without ketanserin — a selective 5-HT2A receptor antagonist. Ketanserin fully blocked both the subjective and neural effects of LSD. When 5-HT2A receptors were pharmacologically blocked, the LSD trip simply did not happen.
How LSD Rewires Brain Connectivity
Beyond receptor binding, fMRI neuroimaging studies have revealed how LSD effects on brain organization differ from the normal resting state. The same Preller et al. (2018) eLife study found that LSD reduces connectivity in associative brain areas — regions involved in abstract reasoning and self-referential thought — while simultaneously increasing connectivity across sensory and somatomotor areas responsible for processing sight, sound, and touch.
A 2022 study published in Nature Communications, applying network control theory to fMRI data, found that LSD and psilocybin flatten the brain’s dynamic landscape — effectively lowering the energy barriers between different brain states and allowing the brain to shift more easily between modes of activity. The authors describe this as creating more temporally diverse brain activity: the brain visits a wider range of states than it normally would. This computational model offers a compelling explanation for why LSD produces such radical alterations in consciousness — not by overwhelming the brain, but by loosening the constraints that normally keep it operating within a narrow range.
LSD and the Default Mode Network
The default mode network (DMN) — the brain’s resting-state network associated with self-referential thought, mind-wandering, and the construction of personal narrative — is significantly disrupted by LSD. Research from Imperial College London has documented that classic serotonergic psychedelics, including LSD, reduce the orderly, hierarchical functioning of the DMN. This disruption correlates with the subjective dissolution of ego boundaries — the feeling that the self is less defined or separate from the environment — which is one of the most distinctive and clinically significant effects of high-dose LSD experiences.
LSD and Neuroplasticity
A 2023 study published in Science by Olsen and colleagues demonstrated that psychedelics including LSD promote cortical neuron growth by activating intracellular 5-HT2A receptors — receptors located inside the cell rather than on its surface membrane. Decreased dendritic spine density in the cortex is a hallmark of depression and PTSD, and the ability of psychedelics to reverse this is now considered a likely mechanism underlying their rapid therapeutic effects in clinical trials. This finding explains why serotonin itself — which primarily activates surface receptors and cannot reach intracellular 5-HT2A sites — does not produce similar neuroplasticity effects.
LSD Visuals & Hallucinations: What They Actually Are
LSD hallucinations are the aspect of the drug’s effects most commonly depicted in popular culture — and most frequently misrepresented. Calling them simply “hallucinations” conflates several distinct phenomena that researchers now classify separately.
Types of LSD Visual Effects
At lower doses, LSD produces what are technically called pseudohallucinations — visual distortions of objects that actually exist, rather than perceptions of things that are entirely absent. These include:
- Geometric patterns and fractals — both with eyes open and closed, arising from LSD’s effect on visual cortex excitability
- Trails and tracers — moving objects leaving visual afterimages
- Enhanced color saturation and vividness — ordinary objects appearing hyper-real in color and texture
- Object morphing and breathing — surfaces appearing to ripple, undulate, or breathe
- Micropsia and macropsia — objects appearing much smaller or larger than they are
At higher doses, true hallucinations — fully formed perceptions of objects, people, or environments that are not present — can occur. These are less common than the distortional effects and are strongly modulated by setting and psychological state.
LSD visuals arise from the drug’s action in the visual cortex, where 5-HT2A receptor density is high. Increased excitability of visual cortical neurons generates patterned activity that the brain interprets as visual input. This is why the geometry of LSD visual phenomena — spirals, lattices, tunnels — follows predictable patterns across different individuals and cultures. Mathematician Jack Cowan’s 1979 model of cortical pattern formation predicted many of these forms before they were systematically documented in psychedelic research.
LSD Side Effects and Risks: What the Evidence Shows
LSD side effects span a wide range from transient and mild to serious and requiring clinical attention. Understanding them accurately requires distinguishing between physiological effects — changes in the body — and psychological effects — changes in mental state.
Physical Side Effects of LSD
LSD produces consistent physiological changes through its action on adrenergic and serotonergic receptors throughout the nervous system. Documented physical LSD symptoms include:
- Pupil dilation (mydriasis) — one of the most reliable physical signs of LSD use
- Elevated heart rate (tachycardia) and increased blood pressure
- Increased body temperature (hyperthermia) — especially at high doses
- Jaw clenching and muscle tension
- Nausea — particularly during onset
- Sweating and chills alternating
- Tremors or fine motor disruption at higher doses
- Insomnia — LSD’s stimulant properties make sleep extremely difficult during the experience
Psychological Side Effects and Risks
LSD side effects in the psychological domain range from uncomfortable to acutely dangerous in vulnerable individuals:
- Anxiety and panic — the most common adverse psychological effect, particularly in unfamiliar settings or among inexperienced users
- Paranoia — feelings of being watched or threatened, common during difficult experiences
- Thought loops — repetitive, intrusive thought patterns that are difficult to interrupt
- Acute psychosis — rare but documented, particularly in individuals with personal or family history of psychotic disorders; the evidence strongly suggests LSD can trigger latent psychiatric conditions
- HPPD (Hallucinogen Persisting Perception Disorder) — a rare condition where visual disturbances persist for weeks, months, or years after cessation of psychedelic use; prevalence estimates range from 0.12% to 4.2% of psychedelic users in clinical surveys
Short-Term and Long-Term LSD Effects
Short-Term Effects
Short-term LSD effects are largely those described above — perceptual, cognitive, emotional, and physiological changes occurring over the 8–12 hour duration of a typical experience. Importantly, the research literature distinguishes between effects that occur during acute intoxication and those that persist in the days following.
In the days immediately following a significant LSD experience, users commonly report what researchers at Johns Hopkins have described as an afterglow — a period of elevated mood, increased openness, and reduced depressive symptoms that can last from 24 hours to several weeks. This afterglow period is considered clinically significant and is one of the reasons psychedelic-assisted therapy protocols typically space sessions several weeks apart.
Long-Term LSD Effects
Long-term effects of LSD are more complex and less systematically studied than acute effects. What the evidence currently supports:
- Personality changes — a 2011 study in the Journal of Psychopharmacology found that a single high-dose psilocybin experience produced lasting increases in the personality trait openness more than a year later; similar findings have been documented with LSD
- Persistent positive changes in values and life satisfaction — reported by a majority of participants in naturalistic surveys who characterized their LSD experiences as among the most meaningful of their lives
- Risk of HPPD in a small minority of users — as noted, visual disturbances can persist long-term
- No evidence of lasting cognitive impairment — large population-based studies have found no association between psychedelic use and cognitive decline or mental health problems in the general population; however, individuals with pre-existing psychotic vulnerability are a meaningful exception
- Potential long-term therapeutic benefits — ongoing clinical trials at Johns Hopkins, NYU, and Imperial College London are specifically investigating sustained therapeutic outcomes from LSD and psilocybin
The critical caveat on long-term research: most long-term data comes from observational studies and surveys rather than controlled trials. The absence of documented harm in population studies is reassuring but not equivalent to a confirmed safety record for all individuals across all use patterns.
Conclusion & Actionable Takeaways
LSD produces some of the most complex and well-studied pharmacological effects of any psychoactive substance — operating through a specific, now well-characterized mechanism at the 5-HT2A serotonin receptor, reorganizing brain connectivity in measurable ways, and producing effects that span every domain of conscious experience. The science is genuinely fascinating and increasingly clinically relevant. Here is what it is important to take away:
- LSD effects are driven primarily by partial agonism at cortical 5-HT2A receptors — this is confirmed by human studies showing ketanserin (a 5-HT2A blocker) fully eliminates both the subjective and neural effects of LSD
- LSD reduces associative brain connectivity and increases sensory connectivity — creating a brain state characterized by greater perceptual richness and reduced self-referential filtering
- LSD visuals and hallucinations arise from increased visual cortex excitability — they are not random but follow predictable patterns that researchers have mapped and modeled mathematically
- Physical LSD side effects include pupil dilation, elevated heart rate and blood pressure, nausea, jaw tension, and insomnia — none are life-threatening at standard doses in healthy individuals
- Psychological risks are real and include anxiety, panic, paranoia, and — in individuals with psychotic vulnerability — the potential triggering of latent psychiatric conditions; this is the most clinically important safety consideration
- HPPD is rare but real — affecting an estimated 0.12–4.2% of psychedelic users; anyone experiencing persistent visual disturbances after psychedelic use should seek evaluation from a psychiatrist familiar with psychedelic medicine
- LSD does not produce physical dependence and is not conventionally addictive — but psychological overuse patterns can develop
- Emerging neuroscience suggests LSD promotes neuroplasticity through intracellular 5-HT2A receptor activation — a mechanism with direct implications for understanding and treating depression and PTSD
- If you are considering psychedelic-assisted therapy, only engage with clinical trial programs or licensed therapeutic settings; do not attempt self-treatment for psychiatric conditions
References
All factual claims in this article are grounded in the following peer-reviewed studies and authoritative institutional sources:
5. Nichols DE. Psychedelics. Pharmacol Rev. 2016 Apr;68(2):264-355. doi: 10.1124/pr.115.011478. PMID: 26841948. PMC: PMC4813425.
6. Dolder PC, Schmid Y, Haschke M, Rentsch KM, Liechti ME. Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects. Clin Pharmacokinet. 2017 Oct;56(10):1219-1230. doi: 10.1007/s40262-017-0513-9. PMID: 28197931.
8. Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016 Jul;3(7):619-627. doi: 10.1016/S2213-2600(16)30065-7. PMID: 27210031.
9. Halpern JH, Lerner AG, Passie T. A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms. Curr Top Behav Neurosci. 2018;36:333-360. doi: 10.1007/7854_2016_457. PMID: 28025812.
10. MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011 Nov;25(11):1453-61. doi: 10.1177/0269881111420188. PMID: 21956378. PMC: PMC3537171.
11. Krebs TS, Johansen PØ. Psychedelics and mental health: a population study. PLoS One. 2013 Aug 19;8(8):e63972. doi: 10.1371/journal.pone.0063972. PMID: 23976938. PMC: PMC3747247.
Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice. LSD is a Schedule I controlled substance in the United States. If you are experiencing a psychiatric emergency, contact emergency services immediately. For substance use support, SAMHSA’s National Helpline is available 24/7 at 1-800-662-4357.